Dr. Kebriaei on the Iomab-B Clinical Trial

Partow Kebriaei, MD
Published: Friday, Feb 24, 2017


Partow Kebriaei, MD, of MD Anderson Cancer Center, discusses the SIERRA clinical trial, in which patients over the age of 55 with acute myeloid leukemia (AML) are receiving treatment with a radiolabeled anti-CD45 antibody known as Iomab-B or conventional therapy as a preconditioning regimen before allogeneic hematopoietic cell transplantation.

The targeted administration of radiation helps to treat older patients with AML, as it is a less intense therapy, notes Kabriaei. This reduced intensity is especially important for older patients, who tend to have less tolerance for toxicities. Iomab-B offers a novel therapy for this population of patients, she adds. 

<<< View more from the 2017 BMT Tandem Meetings

Partow Kebriaei, MD, of MD Anderson Cancer Center, discusses the SIERRA clinical trial, in which patients over the age of 55 with acute myeloid leukemia (AML) are receiving treatment with a radiolabeled anti-CD45 antibody known as Iomab-B or conventional therapy as a preconditioning regimen before allogeneic hematopoietic cell transplantation.

The targeted administration of radiation helps to treat older patients with AML, as it is a less intense therapy, notes Kabriaei. This reduced intensity is especially important for older patients, who tend to have less tolerance for toxicities. Iomab-B offers a novel therapy for this population of patients, she adds. 

<<< View more from the 2017 BMT Tandem Meetings

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x